Get the Weekly Intelligence Brief — top committee picks every Sunday.
PFE · NYSE · STOCK

Pfizer (PFE) Stock Analysis

Healthcare Updated August 23, 2026
$28.07
52W $23.58 – $28.75
48/100
$159.98B
37.1
0.28
AI Committee Verdict
Watch
48/100
Conviction: Contested · 50% agreement · 6 analysts
+2.4%
-0.8%
3.19:1
Contested

Is PFE Bullish or Bearish?

Mixed. Innellis AI committee rates Pfizer Inc. (PFE) Watch with a composite score of 48/100 , based on 6 analysts with 50% agreement. Last updated August 23, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +12.01 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -7.99 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — bollinger bandwidth of 16.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Dividend yield of 5.4% pays you to wait — Value
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
Bear Case
  • P/E of 35.2 is moderate-to-rich — Value
  • ROE of only 4.9% -- cheap may mean cheap for a reason — Value
  • Revenue declining -0.2% YoY -- this is not a growth story right now — Growth
  • EPS declining -59.9% YoY despite any revenue growth — Growth
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • RSI at 74 is in overbought territory — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 23, 2026
Overall Committee Score
48/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 97%
of 192 Healthcare peers
Value Analyst neutral
42 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Dividend yield of 5.4% pays you to wait
− P/E of 35.2 is moderate-to-rich
Growth Analyst bearish
38 / 100 · High confidence
Growth story is weak, decelerating, or inconsistent
+ 5 consecutive earnings beats -- consistent execution
− Revenue declining -0.2% YoY -- this is not a growth story right now
Technical Analyst neutral
51 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 74 is in overbought territory
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 16.8% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 48.0 to 48.0.

Comparing 2026-08-22 to 2026-08-23 (1 day apart).

Technical Analysis

RSI (14)
73.8
Overbought
MACD Histogram
0.183
Bullish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Mixed
Support
$27.86
Resistance
$28.73
Bollinger %B
0.90
Inside Bands
Price vs Moving Averages
EMA 9
$27.31 Above
EMA 21
$26.52 Above
EMA 50
$25.90 Above
EMA 200
$25.82 Above

Fundamental Analysis

Valuation
69
Growth
68
Profitability
54
Financial Health
63
Cash Flow
70
Valuation
P/E Ratio 37.1×
P/B Ratio 1.88×
PEG Ratio -0.62
Dividend Yield 6.13%
52W High $28.75
52W Low $23.58
Quality & Growth
ROE 898.5%
ROA 373.3%
Gross Margin 7132.2%
Operating Margin 2508.2%
Revenue Growth YoY
Debt / Equity 0.74
AI Fundamental Assessment
P/E ratio of 37.1 (rich relative to a 15-40x range); Price-to-book of 1.9x; PEG ratio of -0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 9.0%; Return on assets of 3.7%; Net margin of 6.8%; Gross margin of 71.3%; Current ratio of 1.27 (tight short-term liquidity); Debt-to-equity of 0.74; Free cash flow per share is positive (1.93); Most recent quarter beat estimates by 11.4%; 5 consecutive earnings beats; EPS growth decelerating (+13.6% -> +2.7% QoQ); Average YoY EPS growth of -1.3%; Analyst estimates rising over recent quarters
Get the Full PFE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime